RxDoctor Payments Data

Matthew Flaherty, MD

Vascular Neurology · Cincinnati, OHNPI 1417998584

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $54,172 of the $70,548 with a category attached, or 76.8%. 5 manufacturers reported payments, led by CSL Behring at 59.1% of the total. Reporting peaked in 2019 at $41,199 and has fallen 98.2% since, to $750 in 2025. Among vascular neurology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$70,548in general payments, 2019–2025

Across 77 payments — averaging $916.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$42K
  • Johnson & Johnson$26K
  • Boehringer Ingelheim International GmbH$2K
  • AstraZeneca$12
  • Medtronic$11
$93,423in research payments, 2019–2025

Across 26 payments — averaging $3593.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$67K
  • Boehringer Ingelheim International GmbH$20K
  • Bayer$7K

What the payments were for

  • Consulting fees$3,8906%
  • Speaking & faculty fees$54,17277%
  • Travel & lodging$11,15616%
  • Food & beverage$1,3282%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,548 in reported general payments places this provider in the 95th percentile of 43 vascular neurology providers in Ohio.

See all vascular neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$18,682
Medicare patients
84
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$36,699
BrilintaTicagrelor22$9,634
Carbamazepine ErCarbamazepine12$2,368
Levetiracetam46$1,293
ClopidogrelClopidogrel Bisulfate38$629
Ezetimibe20$628
Pregabalin16$254
Topiramate15$248
Atorvastatin Calcium28$245
Lamotrigine23$190
Gabapentin16$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$12$9,63422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 vascular neurology providers in Ohio.

Other vascular neurology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →